Intratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants: The PLUSS Randomized Clinical Trial

IMPORTANCE: Bronchopulmonary dysplasia (BPD) is a common adverse outcome in extremely preterm infants born at less than 28 weeks’ gestation. Systemic corticosteroids are effective against BPD but may be associated with adverse outcomes. Corticosteroids given directly into the lungs may be effective...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JAMA : the journal of the American Medical Association 2024-11, Vol.332 (22), p.1889
Hauptverfasser:	Manley, Brett J, Kamlin, C. Omar F, Donath, Susan M, Francis, Kate L, Cheong, Jeanie L. Y, Dargaville, Peter A, Dawson, Jennifer A, Jacobs, Susan E, Birch, Pita, Resnick, Steven M, Schmölzer, Georg M, Law, Brenda, Bhatia, Risha, Bach, Katinka P, de Waal, Koert, Travadi, Javeed N, Koorts, Pieter J, Berry, Mary J, Lui, Kei, Rajadurai, Victor S, Chandran, Suresh, Kluckow, Martin, Cloete, Elza, Broom, Margaret M, Stark, Michael J, Gordon, Adrienne, Kodur, Vinayak, Doyle, Lex W, Davis, Peter G, McKinlay, Christopher J. D
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological Products - administration & dosage Biological Products - adverse effects Bronchopulmonary Dysplasia - drug therapy Budesonide - administration & dosage Budesonide - adverse effects Double-Blind Method Female Gestational Age Glucocorticoids - administration & dosage Glucocorticoids - adverse effects Humans Infant, Extremely Premature Infant, Newborn Intubation, Intratracheal Male Phospholipids Pulmonary Surfactants - administration & dosage Respiration, Artificial
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!